Medicenna Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Medicenna Therapeutics has a total shareholder equity of CA$18.6M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$23.3M and CA$4.6M respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$21.76m |
| Equity | CA$18.63m |
| Total liabilities | CA$4.64m |
| Total assets | CA$23.27m |
Recent financial health updates
Recent updates
Medicenna extends period to exercise certain warrants
Sep 30Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment
Sep 13Medicenna Therapeutics GAAP EPS of -$0.07 in-line
Aug 15Medicenna Therapeutics stock slides on launch of units offering
Aug 08Medicenna Therapeutics reports FY results
May 28Medicenna posts positive data from mid-stage brain cancer study
May 07Medicenna announces ATM sales facility for $25M
Dec 31Medicenna Therapeutics reports Q2 results
Nov 13Financial Position Analysis
Short Term Liabilities: MDNA.F's short term assets (CA$23.2M) exceed its short term liabilities (CA$4.6M).
Long Term Liabilities: MDNA.F has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MDNA.F is debt free.
Reducing Debt: MDNA.F had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDNA.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MDNA.F has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 13% each year.